Top 10 Dividend Companies To Buy For 2016

Top 10 Dividend Companies To Buy For 2016: Merck & Company Inc.(MRK)

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company?s Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, diabetes and obesity, infectious diseases, neurosciences and ophthalmology, oncology, vaccines, and women's health and endocrine. This segment also offers human health vaccines, such as preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products. This segment offers antibiotics, anti-inflammatory products, vaccines, products for the treatment of fertility disorders, and parasiticides for cattle, swine, horses, poultry, dogs, cats, salmons, and fish. The Consumer Care segment develops, manufac tures, and markets over-the-counter, foot care, and sun care products. Its over-the-counter product line includes non-drowsy antihistamines; treatment for occasional constipation; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant spray; and treatment for frequent heartburn. This segment?s foot care products comprise topical antifungal, and foot and sneaker odor/wetness products; and sun care products include sun care lotions, sprays and dry oils; and sunburn relief products. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, and managed health care providers, as well as food chain and mass merchandiser outlets in the United States and Canada. Merck & Co., Inc. was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

Advisors' Opinion:

• [By Sean Williams]

  Th! e bad
  Merck (NYSE: MRK  ) delivered rather disappointing news on its late-stage Parkinson's disease medication Preladenant on Thursday, noting that three separate late-stage trials didn't provide any statistical evidence of efficacy relative to the placebo. As such, Merck no longer intends to pursue regulatory approval for Preladenant and plans on shutting down any extension trials. It will, however, present its findings at upcoming scientific meetings.

• [By JulieYoung789]

  In the DJIA financial stocks Visa (V) and Goldman Sachs led the index higher. Visa was up 1.86% ending at $221.03 and Goldman Sachs was up 1.33% ending the day at $167. Laggers in the index included Merck (MRK) which was down 0.44% to $58.18 and Wal-Mart (WMT) which was down 0.35% to $76.55.

• [By Keith Speights]

  Although it has no commercialized drugs to generate revenue, Lexicon has been able to keep going through the years by forming relationships with larger organizations. For example, Lexicon and Merck (NYSE: MRK  ) have worked together for several years to develop biotherapeutic drugs. The partnership with Merck has netted Lexicon $52.5 million in revenue for development.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-10-dividend-companies-to-buy-for-2016.html